IP Library Granted Patent US 8,515,560
Granted Patent B2
US 8,515,560 · App. 10/536,714 · Granted Aug 20, 2013

Medical implant drug delivery device

Inventors: Kristine Debruyne (Mechelen, BE); Dirk Fiedler (Lane Cove, AU); Thomas Kaiser (Mechelen, BE); Ben Kloeck (Mechelen, BE); Dusan Milojevic (Westleigh, AU); John Parker (Roseville, AU)
Assignee: Cochlear Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,515,560
App. No.
10/536,714
Granted
Aug 20, 2013
Kind
B2
Abstract

Devices for the delivery of a bioactive substance to a cochlea and methods of delivery thereof. The devices include means to allow the release of the bioactive substance within a cochlea.

Claims (27)

1. An implantable tissue stimulating device comprising:

an electrode assembly comprising a lead and an elongate member having its proximal end contiguous with a distal end of the lead, and having one or more electrodes disposed on or in the elongate member; and

a slider means for delivery of a bioactive substance slidably mounted on the lead such the lead extends through the slider means, the slider means configured to receive a bioactive substance and deliver the bioactive substance to a target site in the recipient.

2. The device of claim 1 , further comprising:

a stop member, disposed on the electrode assembly, configured to prevent the slider means from sliding beyond the stop member toward a distal end of the elongate member.

3. The device of claim 1 , wherein a portion of the lead is configured to be implanted in a middle ear of the recipient, and wherein the slider means is dimensioned to slide along a portion of the lead implanted in the middle ear.

4. The device of claim 1 , wherein the slider means has a plurality of different diameters along the length of the slider means.

5. The cochlear implant of claim 1 , wherein the slider means includes a chamber configured to receive a bioactive substance and configured to retain the bioactive substance therein for a period of time.

6. The cochlear implant of claim 5 , wherein the chamber is annular and surrounds a lumen of the slider means through which the electrical lead passes.

7. The device of claim 5 , wherein the slider means further comprises:

an outlet in fluid communication with the chamber; and

a semi-permeable membrane disposed in the outlet and configured to leach the bioactive substance from the chamber to the target site.

8. The device of claim 5 , wherein the slider means further comprises:

an inlet in fluid communication with the chamber.

9. The cochlear implant of claim 8 , wherein the slider means further comprises:

an outlet in fluid communication with the chamber,

wherein the chamber is configured to pass the bioactive substance from the inlet to the outlet.

10. The cochlear implant of claim 8 , wherein the inlet is disposed in a proximal end of the slider means, and the outlet is disposed in a distal end of the slider means.

11. The cochlear implant of claim 10 , wherein the chamber is a pipe extending through the slider means from the inlet to the outlet.

12. The device of claim 1 , wherein:

the device is a cochlear implant.

13. A cochlear implant comprising:

a stimulator unit configured to generate electrical stimulation signals;

an electrode assembly comprising a lead extending from the stimulator unit, and a contiguous elongate member implantable in a recipient's cochlea;

one or more electrodes disposed on or in the elongate member each configured to deliver the electrical stimulation signals to the cochlea; and

an annular collar slidably mounted around the lead such that the lead extends through a lumen in the collar, the collar having a non-porous cavity therein configured to receive a bioactive substance and an outlet located on an exterior face of the collar through which the bioactive substance can pass from the cavity to a target site in the recipient,

wherein the outlet faces the electrode assembly and forms a boundary of the cavity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2021
From: FIEDLER, DIRK; KAISER, THOMAS; KLOECK, BEN; MILOJEVIC, DUSAN; PARKER, JOHN; DEBRUYNE, KRISTINE
To: COCHLEAR LIMITED
Reel/Frame 055959/0318 →
Priority Claims (3)
AU 2002952995 · Nov 29, 2002 · national
AU 2002952997 · Nov 29, 2002 · national
AU 2002952998 · Nov 29, 2002 · national
Continuity (1)
Related Publication 20060287689A1 · Dec 21, 2006